Related Party Transactions

9 Months Ended

Sep. 30, 2023

Related Party Transactions [Abstract]

Related Party Transactions

Related Party Transactions

Founder Consulting Services

For both the three months ended September 30, 2023 and 2022, the Company made payments of $37,500 in each period, and for the nine months ended September 30, 2023 and 2022, the Company made payments of $112,500 in each period to one of the co-founder stockholders for scientific consulting and other expenses. As of September 30, 2023, $12,500 was included within accounts payable, and, as of December 31, 2022, there were no amounts included within accounts payable.

Myeloid Therapeutics

In December 2021, the Company and Myeloid Therapeutics, Inc. (“Myeloid”) entered into the Myeloid Collaboration Agreement and Myeloid Subscription Agreement. The Company and Myeloid have one common board member, who is also an affiliate of Newpath, one of the Company’s holders of its common stock. The Company provided notice to Myeloid of its intent to terminate the Myeloid Collaboration Agreement during the second quarter of 2023, which termination is now effective. As of September 30, 2023, there was $0.1 million in

accounts payable, and, as of December 31, 2022, there was $0.3 million included within accrued expenses and other current liabilities related to license fees.